Global Information
회사소개 | 문의 | 비교리스트

시장 스포트라이트 : 신경내분비종양(NET)

Market Spotlight: Neuroendocrine tumors (NET)

리서치사 Datamonitor Healthcare
발행일 2021년 05월 상품코드 939993
페이지 정보 영문 42 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 1,318 ₩ 1,905,000 PDF (Single User License)


시장 스포트라이트 : 신경내분비종양(NET) Market Spotlight: Neuroendocrine tumors (NET)
발행일 : 2021년 05월 페이지 정보 : 영문 42 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

Datamonitor Healthcare는 2019년에 세계에서 약 531,400건의 신경내분비종양(NET) 증례가 발생한 것으로 추정하며, 그 수는 2028년까지 639, 200건으로 증가할 것으로 예측하고 있습니다. 2019년 NET의 대부분은 악성 카르시노이드 종양 또는 신경내분비암이었습니다.

신경내분비종양(NET)의 주요 출시약·파이프라인약, 최근 동향과 애널리스트의 견해, 임상시험, 성공 가능성, 향후 동향·규제 동향, 특허 정보, 10년간 발생률 예측, 라이선싱·자산 취득 거래 및 의약품별 매출 예측 등에 대해 분석하여 전해드립니다.

개요

요점

질환 배경

  • 서브타입별

치료

  • 수술
  • 간동맥색전술
  • 소마토스타틴 유사체
  • 인터페론 알파(IFN-알파)
  • 화학요법
  • 방사선 치료
  • 표적치료
  • 완화 케어

역학

  • 발생률의 조사 방법
  • 질환의 정의
  • 유병률의 조사 방법

출시약

파이프라인약

최근 동향·애널리스트의 견해

  • TBR-760

주요 규제 동향

  • RadioMedix, PET 진단약의 리뷰를 우선
  • University of Iowa의 PET 센터가 NME 승인을 취득

성공 확률

라이선싱·자산 인수 거래

모특허

매출 기회

임상시험 환경

  • 스폰서 : 스테이터스별
  • 스폰서 : 단계별
  • 최근 동향

문헌

부록

KSA 20.06.23

This Market Spotlight report covers the Neuroendocrine Tumors (NETs) market, comprising key marketed and pipeline drugs, clinical trials, probability of success, upcoming and regulatory events, a 10-year disease incidence and prevalence forecast, and licensing and asset acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Datamonitor Healthcare estimates that in 2019, there were approximately 531,400 incident cases of neuroendocrine tumors (NETs) worldwide, and forecasts that number to increase to 639,200 incident cases by 2028.

Worldwide, the majority of NETs in 2019 were malignant carcinoid tumors or neuroendocrine carcinomas. The approved drugs in the NETs space focus on targets such as norepinephrine (noradrenaline), radiopharmaceutical, mammalian target of rapamycin/mTORC, tyrosine hydroxylase, somatostatin receptors, FMS-like tyrosine kinase 3, KIT/c-KIT, platelet-derived growth factor receptor, VEGF receptor, ganglioside GD2, tryptophan hydroxylase, cluster of differentiation 3, fibroblast growth factor receptor, and macrophage colony stimulating factor 1. These drugs are predominantly administered via the oral, intravenous, and subcutaneous routes, while one product is available in an intramuscular formulation.

The majority of industry-sponsored drugs in active clinical development for NETs are equally distributed between Phase I and Phase II, with one drug in the NDA/BLA stage.

Therapies in the pipeline for NETs focus on a wide variety of targets. The largest proportion of these therapies are administered intravenously, with the remainder being oral, subcutaneous, intranasal, and intratumoral formulations.

High-impact upcoming events for drugs in the NETs space comprise topline Phase II trial results for ABI-009 and an expected PDUFA date for surufatinib.

The overall likelihood of approval of a Phase I solid tumors asset is 5.3%, and the average probability a drug advances from Phase III is 42.8%. Drugs, on average, take 9.7 years from Phase I to approval, compared to 9.6 years in the overall oncology space.

The distribution of clinical trials across Phase I-IV indicates that the majority of trials for NETs have been in the early and midphases of development, with 78% of trials in Phase I-II, and only 22% in Phase III-IV.

The US has a substantial lead in the number of NETs clinical trials globally. Spain leads the major European markets, while China has the top spot in Asia.

Novartis has the highest number of completed clinical trials for NETs, with 23 trials. Novartis also leads industry sponsors with the highest overall number of clinical trials for NETs, followed by Ipsen.

TABLE OF CONTENTS

CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

  • Subtypes

TREATMENT

  • Surgery
  • Hepatic artery embolization
  • Somatostatin analogs
  • Interferon-alpha (IFN-alpha)
  • Chemotherapy
  • Radiation therapy
  • Targeted therapy
  • Immunotherapy
  • Palliative care

EPIDEMIOLOGY

  • Incidence methodology
  • Epidemiological disease definition
  • Prevalence methodology

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Keeping Track: Gavreto, Sogroya Bring Annual CDER Novel Approvals To 40

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

  • Lexicon Sells Cancer Supportive Care Therapy To TerSera

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of NETs, 2019-28
  • Figure 2: Incident cases of NETs, by tumor type, 2019
  • Figure 3: Overview of pipeline drugs for NETs in the US
  • Figure 4: Pipeline drugs for NETs, by company
  • Figure 5: Pipeline drugs for NETs, by drug type
  • Figure 6: Pipeline drugs for NETs, by classification
  • Figure 7: Key upcoming events in NETs
  • Figure 8: Probability of success in the solid tumors pipeline
  • Figure 9: Clinical trials in NETs
  • Figure 10: Top 10 drugs for clinical trials in NETs
  • Figure 11: Top 10 companies for clinical trials in NETs
  • Figure 12: Trial locations in NETs
  • Figure 13: NETs trials status
  • Figure 14: NETs trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of NETs, 2019-28
  • Table 2: Five-year prevalent cases of NETs, 2019-28
  • Table 3: Marketed drugs for NETs
  • Table 4: Pipeline drugs for NETs in the US
  • Table 5: Historical global sales, by drug ($m), 2016-20
  • Table 6: Forecasted global sales, by drug ($m), 2021-25
Back to Top
전화 문의
F A Q